开盘$3.59
昨收$3.50
当日区间$3.48 – $3.65
成交量15.59M
市值$2.19B
市盈率（TTM）–
股息率–
RXRX 相关新闻
匹配 Recursion Pharmaceuticals 或代码 RXRX 的头条新闻，按最新排序。
- BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
- Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)
- J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating
- Recursion Pharmaceuticals (RXRX) Gets a Hold From Bank of America Securities
- TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
- Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8
- Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 负面
- BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6
- Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5 正面
- J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10 负面
- BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $6 负面
- Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HERSHBERG ROBERT
- Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake
- Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8
暂无评论——快来第一个聊聊 RXRX。